CellCentric vs Slate Medicines
CellCentric vs Slate Medicines, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CellCentric is on 60/100 and Slate Medicines on 41/100.
Where each one leads
CellCentric
- our overall score: 60/100 against 41/100
- domain rating: 35/100 against 14/100
- funding raised: $375M against $130M
Slate Medicines
- agent readiness: 51/100 against 32/100
At a glance
| Measure | CellCentric | Slate Medicines |
|---|---|---|
| What it is | A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma. | Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders. |
| Category | Biotechnology, Pharmaceuticals, Healthcare, Biotech | Biotechnology, Pharmaceuticals, Therapeutics, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Services |
| Founded | 2003 | 2024 |
| Headquarters | Cambridge, United Kingdom | Cambridge, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CellCentric | Slate Medicines |
|---|---|---|
| Employees | 53 | Not published |
| Total funding | $375M | $130M |
| Latest round | Series D | Series A |
| LinkedIn followers | 28,695 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CellCentric | Slate Medicines |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 41/100 |
| Traction | 57/100 | 40/100 |
| Team | 60/100 | 30/100 |
| Search visibility | 44/100 | 14/100 |
| Quality | 68/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (32/100) | D (51/100) |
| Domain ratingLink authority, 0-100 | 35/100 | 14/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CellCentric | Slate Medicines |
|---|---|---|
| CDN | Cloudflare | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Google Analytics 4 | Google Analytics 4 |
CellCentric vs Slate Medicines: common questions
Which is better, CellCentric or Slate Medicines?
On our 0-100 score CellCentric rates higher (60/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do CellCentric and Slate Medicines compare on the numbers?
CellCentric leads on our overall score (60/100 against 41/100), domain rating (35/100 against 14/100), funding raised ($375M against $130M). Slate Medicines leads on agent readiness (51/100 against 32/100).
Read the full CellCentric review and pricing or the Slate Medicines review and pricing. You can also browse other CellCentric alternatives we track.